Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate

Number Of Firms Financed Fell From A Year Ago

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.

Venture capital. Long term business investment
M&A and IPO activity could further boost VC activity in 2024 • Source: Shutterstock

Biopharmaceutical companies have raised one venture capital mega-round after another in 2024 – with several of the $100m-plus financings often announced on the same day – and first quarter VC fundraising data from Evaluate show that big bets placed by investors on drug developers during the quarter added up to a rebound in venture financing.

Key Takeaways

  • Venture capital fundraising rose from $4.21bn in the first quarter of 2023 to $6bn in Q1 of 2024, but the number of financings fell as fewer companies raised larger rounds.

A review of Evaluate’s database showed that biopharma companies raised $6bn in venture capital during Q1, including $3.74bn worth of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.